Literature DB >> 4219766

Properdin levels in systemic lupus erythematosus and membranoproleferative glomerulonephritis.

L H Perrin, P H Lambert, P A Miescher.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4219766      PMCID: PMC1554001     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  20 in total

1.  Reaction mechanism of the alternative pathway of complement fixation.

Authors:  P J Lachmann; P Nicol
Journal:  Lancet       Date:  1973-03-03       Impact factor: 79.321

2.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

3.  [Activation of complement in membrano-proliferative glomerulonephritis].

Authors:  L H Perrin; P H Lambert; G Lagrue; M J Auderset; F M Machnik
Journal:  J Urol Nephrol (Paris)       Date:  1973-10

4.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

Review 5.  Complement in human disease.

Authors:  P H Schur; K F Austen
Journal:  Annu Rev Med       Date:  1968       Impact factor: 13.739

6.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

7.  Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus.

Authors:  P F Kohler; R Ten Bensel
Journal:  Clin Exp Immunol       Date:  1969-02       Impact factor: 4.330

8.  Glomerular deposition of properdin in acute and chronic glomerulonephritis with hypocomplementemia.

Authors:  N G Westberg; G B Naff; J T Boyer; A F Michael
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

9.  Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.

Authors:  R H McLean; A F Michael
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

10.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  11 in total

1.  Immune complexes and complement hypercatabolism in patients with leprosy.

Authors:  B Bjorvatn; R S Barnetson; G Kronvall; R H Zubler; P H Lambert
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

2.  Membranoproliferative glomerulonephritis. Localization of early components of complement in glomerular deposits.

Authors:  B K Davis; T Cavallo
Journal:  Am J Pathol       Date:  1976-08       Impact factor: 4.307

3.  Heterogeneity of the clinical syndrome in patients with systemic lupus erythematosus and genetic deficiency of the second complement component.

Authors:  R I Rynes; R E Urizar; R J Pickering
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

4.  Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease.

Authors:  R H Zubler; U Nydegger; L H Perrin; K Fehr; J McCormick; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

5.  Metabolism of properdin in normal subjects and patients with renal disease.

Authors:  J B Ziegler; F S Rosen; C A Alper; W Grupe; I H Lepow
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

6.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

7.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

8.  Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course.

Authors:  A J Swaak; A van Rooyen; C Vogelaar; M Pillay; E Hack
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

Review 9.  Recent advances in the immunopathogenesis of systemic lupus erythematosus.

Authors:  E J Bardana; B Pirofsky
Journal:  West J Med       Date:  1975-02

10.  Clinical and functional consequences of anti-properdin autoantibodies in patients with lupus nephritis.

Authors:  M Radanova; G Mihaylova; D Ivanova; M Daugan; V Lazarov; L Roumenina; V Vasilev
Journal:  Clin Exp Immunol       Date:  2020-05-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.